National Institute on Drug Abuse (NIDA)
A. Drug discovery and development-enabling activities: Development of innovative technologies, methods or tools, including but not limited to:
1. Innovative in vitro, in situ, or in vivo tools for the molecular analysis of the central nervous system, normal and/or diseased.
2. Tools to simplify drug design through the use of advanced computing (simulation) methods.
3. Novel analytical technologies and methods that enhance the understanding of basic mechanisms of drug action and improve drug testing; technologies designed to overcome the performance limitations of current drug discovery and development tools.
4. Technologies, including molecular imaging, gene expression profiling, and genotyping and sequencing approaches designed to better inform the diagnosis and treatment of substance use disorders
B. Drug discovery and development activities: Application of emerging and existing technologies and platforms to Substance Use Disorder (SUD) drug development. Medical products with potential to minimize drug seeking, compulsive behavior, and/or addictive processes. Examples might include, but are not limited to:
1. Chemistry / pharmaceutical drug development
2. Formulation and/or enhanced delivery of drugs
3. Preclinical and/or clinical drug development
4. Identification and development of biomarkers related to SUD treatment outcomes
- Agency: Department of Health and Human Services,Department of Health and Human Services
- Program: SBIR
- Phase: Phase I
- Release Date: August 05, 2015
- Open Date: August 05, 2015
- Close Date: April 05, 2016
- URL: https://grants.nih.gov/grants/guide/pa-files/PA-15-269.html